

BIOTECH, DEVELOPING AND DEVELOPED COUNTRIES VACCINE MANUFACTURERS COVID-19 PRESS BRIEFING

End of year COVID-19 vaccine manufacturing update and challenges for 2022

When: Thursday 16 December 2021

14:00 – 15:30 CET (Geneva); 8:00 – 9:30 EST (Washington D.C); 18:30 – 20:00 IST (Hyderabad)

The Biotechnology Innovation Organization ([BIO](#)), Developing Countries Vaccine Manufacturers Network ([DCVMN](#)) and the International Federation of Pharmaceutical Manufacturers and Associations ([IFPMA](#)) are all [COVID-19 vaccine manufacturers partners of COVAX](#). The press briefing, hosted by IFPMA, will take stock of the progress achieved in developing and scaling up COVID-19 vaccines production, and address the challenges that need to be tackled to achieve equitable access to COVID-19 vaccines.

Speaker line-up:

- [Thomas Cueni](#), Director General, International Federation of Pharmaceutical Manufacturers & Associations ([IFPMA](#))
- [Dr Michelle McMurry-Heath](#), President & CEO, Biotechnology Innovation Organization ([BIO](#))
- [Sai Prasad](#), Executive Director, Quality Operations, Bharat Biotech, President, Developing Countries Vaccine Manufacturers' Network ([DCVMN](#))

With introduction of data by [Rasmus Bech Hansen](#), CEO & Founder, Airfinity.

Press briefing format:

Interventions by speakers (45 min) followed by journalist questions (45 min).

Sign-in guidance:

- Journalists are invited to **register their interest in joining using [this link](#)**. You will receive a link to connect prior to the press briefing.
- Questions sent before Thursday 16 December, 09:00 CET at a.jones@ifpma.org will be given priority.
- Questions during the press briefing can be submitted using the chat function on Vimeo.
- When submitting your questions, please type in your Name Surname and Media Outlet, which will allow us to follow-up on your question should it not be possible to cover it during the briefing itself.
- Journalists will be able to download media materials and the press release on IFPMA website (tab "Upcoming IFPMA events / IFPMA Press Briefings"). These will be under embargo until 14:00 PM CET when the briefing starts.

The recording will be made available on the IFPMA YouTube page and all press materials will be published on www.ifpma.org.

2021 Media Briefings:

- [Biotech, Developing and Developed Countries Vaccine Manufacturers COVID-19 Press Briefing \(23 April 2021\)](#) (23 April 2021)
- [Virtual Press Briefing following the Global COVID-19 Vaccine Supply Chain & Manufacturing Summit](#) (9 March 2021)

[About BIO](#)

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.

[About DCVMN](#)

Developing Countries Vaccine Manufacturers' Network (DCVMN) is a voluntary public health-driven alliance of vaccine manufacturers from developing countries, firmly engaged in research, development, manufacturing and supply of high-quality vaccines that are accessible to protect people against known and emerging infectious diseases globally.

[About IFPMA](#)

IFPMA represents the research-based pharmaceutical companies and associations across the globe. IFPMA collaborates with the United Nations and other organisations to contribute to industry expertise in helping the global health community find solutions that improve global health. IFPMA is a founding partner of the Access to COVID-19 Tools ([ACT](#)) [Accelerator](#) of which the COVID-19 Vaccine Global Access Facility ([COVAX](#)) is a key pillar. IFPMA members are fully committed to the goal of COVAX to accelerate development, production, and equitable access to safe, effective, and affordable COVID-19 vaccines.

Press contacts

Abigail Jones

a.jones@ifpma.org

+32 475 41 09 76

Jacy Gomez

jgomez@bio.org